1h Free Analyst Time
The publisher has been monitoring the scleroderma therapeutics market and it is poised to grow by $ 573.87 mn during 2022-2026, progressing at a CAGR of 5.44% during the forecast period. This report on the scleroderma therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high unmet medical needs, rising focus on awareness-raising initiatives, and increased funding for R and D activities.
The scleroderma therapeutics market analysis includes disease segment and geographic landscape.
The scleroderma therapeutics market is segmented as below:
By Disease Type
- Localized Scleroderma
- Systemic Scleroderma
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the introduction of stem cell therapy in scleroderma treatment as one of the prime reasons driving the scleroderma therapeutics market growth during the next few years. Also, the advent of novel therapies, partnerships, and strategic alliances will lead to sizable demand in the market.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
This report on the scleroderma therapeutics market covers the following areas:
- Scleroderma therapeutics market sizing
- Scleroderma therapeutics market forecast
- Scleroderma therapeutics market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading scleroderma therapeutics market vendors that include AbbVie Inc., Akashi Therapeutics, Amneal Pharmaceuticals Inc., Antares Pharma Inc., Argentis Pharmaceuticals LLC, AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Castle Creek Biosciences Inc., Chemomab Therapeutics Ltd., Corbus Pharmaceuticals Holdings Inc., Cumberland Pharmaceuticals Inc., Emerald Health Pharmaceuticals, F. Hoffmann La Roche Ltd., Kadmon Holdings Inc., Medexus Pharmaceuticals Inc., Novartis AG, Pfizer Inc., and The Procter and Gamble Co. Also, the scleroderma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Disease Type
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
List of Exhibits
Executive Summary
The Publisher Announces the Publication of its Research Report - Global Scleroderma Therapeutics Market 2022-2026The publisher recognizes the following companies as the key players in the global scleroderma therapeutics market: AbbVie Inc., Akashi Therapeutics, Amneal Pharmaceuticals Inc., Antares Pharma Inc., Argentis Pharmaceuticals LLC, AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Castle Creek Biosciences Inc., Chemomab Therapeutics Ltd., Corbus Pharmaceuticals Holdings Inc., Cumberland Pharmaceuticals Inc., Emerald Health Pharmaceuticals, F. Hoffmann La Roche Ltd., Kadmon Holdings Inc., Medexus Pharmaceuticals Inc., Novartis AG, Pfizer Inc., and The Procter and Gamble Co.
Commenting on the report, an analyst from the publisher said: 'The latest trend gaining momentum in the market is the introduction of stem cell therapy in scleroderma treatment.'
According to the report, one of the major drivers for this market is the high unmet medical needs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Akashi Therapeutics
- Amneal Pharmaceuticals Inc.
- Antares Pharma Inc.
- Argentis Pharmaceuticals LLC
- AstraZeneca Plc
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co.
- Castle Creek Biosciences Inc.
- Chemomab Therapeutics Ltd.
- Corbus Pharmaceuticals Holdings Inc.
- Cumberland Pharmaceuticals Inc.
- Emerald Health Pharmaceuticals
- F. Hoffmann La Roche Ltd.
- Kadmon Holdings Inc.
- Medexus Pharmaceuticals Inc.
- Novartis AG
- Pfizer Inc.
- The Procter and Gamble Co.
